Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Advanced ENT and Allergy, PLLC

Neither a doctor nor a teaching hospital

Research payments

$382,789

57 payments

Through program year 2025, Advanced ENT and Allergy, PLLC is reported as receiving $382,789 in research payments, across 57 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $354 1
2024 Research $2,599 4
2023 Research $20,379 8
2022 Research $30,815 4
2021 Research $105,724 21
2020 Research $107,414 17
2019 Research $115,505 2

Breakdown

Who paid Research payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $197,347 9 payments
  2. OptiNose US, Inc. $90,356 11 payments
  3. Smith+Nephew, Inc. $88,086 34 payments
  4. Aerin Medical Inc. $7,000 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Multicenter Randomized Double Blind Parallel Group Placebo Controlled Phase 3 Efficacy and Safety Study Of Benralizumab in Patients with Severe Nasal Polyposis OSTRO $167,730 6 payments
  2. A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 g of OPN-375 Twice a Day (BID) in Subjects with Chronic Sinusitis With or Without the Presence of Nasal Polyps. OPN-FLU-CS-3205. $82,752 9 payments
  3. OTTER pivotal study $76,220 20 payments
  4. A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo- Controlled Phase 3 Efficacy and Safety Study of Benralizumab in Patients with Eosinophilic Chronic Rhinosinusitis with Nasal Polyps (ORCHID) $25,117 2 payments
  5. Tula Registry $11,213 12 payments
  6. A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 g of OPN-375 Twice a Day (BID) in Subjects with Chronic Sinusitis Without the Presence of Nasal Polyps. OPN-FLU-CS-3206. $7,604 2 payments
  7. Ctp1078 - PNN 2-Year $7,000 3 payments
  8. A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Benralizumab for the Prevention of Recurrence of Nasal Polyps Following Surgical Removal in Patients with Chronic Rhinosinusitis with Nasal Polyps (OXALIS) $4,500 1 payment
  9. Earset Study $653 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record